Detected ·
Altay Therapeutics
$37M—
Altay Therapeutics closed a $37 million Series A financing, co-led by HealthCap and Sound Bioventures, to advance DX5057, the first oral DUX4 inhibitor for FSHD, into clinical development.
- Website
- —
- —
- Amount
- $37 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-14 20:05:32 UTC
- Signal ID
- 14ad967a-7dfa-457e-96f9-3bfe007ef93e
As the API returns it
{
"id": "14ad967a-7dfa-457e-96f9-3bfe007ef93e",
"created_at": "2026-10-14T20:05:32.871322Z",
"company_name": "Altay Therapeutics",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 37000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Altay Therapeutics closed a $37 million Series A financing, co-led by HealthCap and Sound Bioventures, to advance DX5057, the first oral DUX4 inhibitor for FSHD, into clinical development.*"
}